Drugs
Conditions
Articles
Researchers from the UK and France used data from the Health Improvement Network database from general practices in the UK. Of 175,195 patients included in their analysis, approximately a quarter (44,699) had been prescribed quinine for idiopathic muscular cramps or restless leg syndrome for at least one year.
The median daily quinine dose was 203mg. Over a median follow-up period of 5.7 years, quinine exposure was associated with 4.2 deaths per 100 person–years, compared with a rate of 3.2 deaths per 100 person–years for unexposed individuals (adjusted hazard ratio 1.24, CI 1.21–1.27). These findings suggest the risk of death could be significantly increased with long-term use of quinine.
Poor risk–benefit ratio
The authors acknowledge that their findings could reflect unmeasured confounders that may predispose patients to higher mortality. However, they concluded, "the benefits of quinine in reducing cramps should be balanced against the risks."
Owing to the poor benefit-to-risk ratio, both NICE CKS and the MHRA advise that quinine should not be considered a routine treatment for nocturnal leg cramps, and should only be considered when self-care measures fail and cramps cause regular disruption of sleep.
If GPs choose to prescribe quinine for this indication, CKS recommends a dose of 200–300mg at bedtime for 4–6 weeks. If this is beneficial, treatment may be continued with review every 3–6 months.
